Test Price
800 AED✅ Home Collection Available
Warfarin Therapeutic Response Predictive Assay (VKORC1 & CYP2C9) in UAE | 800 AED | Genetic Dosing Guidance
Executive Summary & Core Metrics
This pharmacogenetic assay analyzes VKORC1 and CYP2C9 gene polymorphisms to classify warfarin metabolism phenotypes, enabling personalized dosing that minimizes bleeding and thromboembolic events. Conducted at DNA Labs UAE, a DHA-licensed facility (License No: 1143) in Dubai Healthcare City.
We offer VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Test Overview & Methodology
The Warfarin Response Predictive Assay is a targeted pharmacogenetic test that examines specific single nucleotide polymorphisms (SNPs) in the VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes. These genes are critical determinants of warfarin sensitivity and metabolism.
By identifying variants such as the VKORC1 -1639G>A and CYP2C9 *2 (rs1799853) and *3 (rs1057910) alleles, the test categorizes patients into normal, intermediate, or poor metabolizer phenotypes. This genotype-guided stratification allows clinicians to calculate a genetically informed starting dose, significantly reducing the time required to achieve a stable therapeutic International Normalized Ratio (INR).
Our laboratory utilizes Endpoint Polymerase Chain Reaction (PCR) coupled with Restriction Fragment Length Polymorphism (RFLP) analysis, the gold standard methodology for clinical pharmacogenetic typing, ensuring analytical sensitivity and specificity exceeding 99.9%.
| Feature | Our Test – Precision Genetics | Alternative – Empiric INR Dosing |
|---|---|---|
| Precision | 99.9% sensitivity & specificity for VKORC1 & CYP2C9 | No genetic insight; trial-and-error based on INR |
| Method | Endpoint PCR + RFLP (Gold Standard PGx Typing) | Standard coagulation tests without genotyping |
| Speed to Stable Dose | Results in 3–4 working days; guidance from first dose | Dose adjustment takes weeks to months |
| Regulatory Compliance | DHA Licensed, ISO 9001:2015, UAE PDPL Aligned | Standard laboratory INR monitoring |
Physician Insight & Safety Protocols
“Based on my extensive experience in clinical genetics and pharmacogenomics, genotype-guided warfarin dosing is a significant advancement in precision medicine. However, it must be interpreted as a complementary tool—not a standalone solution. The genetic result should always be correlated with clinical factors such as age, dietary vitamin K intake, liver function, and concomitant medications. Patients must never alter their therapy independently; all dose adjustments require a shared decision with the treating physician.”
— Ms. Lina Osama Zaki Quteineh, Consultant Medical Genetics
DHA Registration ID: 9294403 | DNA Labs UAE
Medication Advisory
⚠️ Medication Warning: Do not discontinue prescribed warfarin or adjust your dosage without first consulting your doctor. Abrupt changes in anticoagulation therapy can lead to severe thromboembolic or hemorrhagic complications.
Exclusion Criteria & Emergency Red Flags
- Active major bleeding or diagnosed coagulation disorders.
- Known hypersensitivity to blood draw components or history of severe vasovagal syncope.
- Acute thromboembolic event requiring immediate hospitalization or surgical intervention.
- Severe hepatic impairment (Child-Pugh Class C) or end-stage renal disease (ESRD) where genotype-guided dosing alone is insufficient.
- Pregnancy and lactation (test requires a valid prescription and obstetric consultation).
- 🚨 Emergency Red Flags: If you experience sudden severe headache, black or tarry stools, haematuria, uncontrolled bruising, or haematemesis, stop non-essential activity and call 998 or proceed to the nearest emergency department immediately.
Note: A doctor’s prescription is required for this test. For surgical pre-assessment, travel abroad, or specific clinical guidance, the prescription requirement may be adjusted per clinic policy.
Patient FAQ & Clinical Guidance
1. What is the Warfarin Response Predictive Assay and why is it needed?
This pharmacogenetic test analyzes specific genetic markers in the VKORC1 and CYP2C9 genes to predict how your body metabolizes warfarin. It is essential for identifying your optimal starting dose, reducing the high risk of bleeding or clotting associated with standard trial-and-error dosing methods.
2. How should I prepare for the test and are there any special requirements?
No fasting or special dietary preparation is required for the blood draw. However, you must bring a valid doctor’s prescription to the appointment. Please inform the phlebotomist of any anticoagulant medications (e.g., warfarin, heparin) you are currently taking.
3. How will the results change my warfarin dose?
The results classify you as a normal, intermediate, or poor metabolizer (for CYP2C9) and sensitive or resistant (for VKORC1). Your doctor will use this combined genotype to calculate the most appropriate initial warfarin dose, allowing for a safer and faster achievement of a therapeutic INR level.
4. What do the metabolism phenotypes mean for my long-term treatment?
The phenotype classification provides a baseline for your metabolic capacity. For example, poor metabolizers (CYP2C9) require significantly lower warfarin doses to avoid toxicity, while VKORC1 variants may indicate higher or lower sensitivity. Regular INR monitoring remains essential, but your doctor will have a much safer starting point tailored to your genetic profile.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE is fully committed to the highest standards of data security and patient confidentiality. Our handling of genetic data strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing, patient consent, and safety protocols are conducted in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic information is processed under stringent encryption and access control protocols.
Clinical & Logistical Metadata
| Test Name | Warfarin Therapeutic Response Predictive Assay (VKORC1 & CYP2C9) |
| Price (AED) | 800 AED |
| Turnaround Time | 3–4 Working Days |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) |
| Methodology Used | Endpoint PCR + RFLP |
| ICD-10-CM Code | Z13.89 |
| LOINC Code | 93025-6 |
| DHA Facility License & Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians